Stem cell heart failure success

From BioCentury:

Vericel cell therapy meets in heart failure trial
Vericel Corp. (NASDAQ:VCEL) jumped $1.83 (86%) to $3.95on Thursday after it said cell therapy ixmyelocel-T met the primary endpoint of significantly reducing clinical cardiac events vs. placebo in the Phase IIb ixCELL-DCM trial to treat heart failure due to ischemic dilated cardiomyopathy (DCM).
Specifically, trans-endocardial catheter-based injections of ixmyelocel-T significantly reduced the number of all-cause deaths, CV hospitalizations or unplanned outpatient and ER visits vs. placebo over the 12 months posttreatment among 114 patients with acute decompensated heart failure.
Vericel said the incidence of adverse events was comparable between the trial’s ixmyelocel-T and placebo groups. The company plans to present full data at the American College of Cardiologymeeting in April.
Ixmyelocel-T is an autologous cell therapy made from a patient’s bone marrow containing adult stem and progenitor cells using Vericel’s Tissue Repair Cell technology. According to Vericel, the company’s manufacturing process expands mesenchymal stromal cells and M2-like macrophages while retaining hematopoietic cells. Back to top